| PD-1 is an immunosuppressive receptor on activated T and B cells, essential for regulating immune responses to tumor antibodies and self-antigens. Its interaction with ligands PD-L1 or PD-L2 inhibits TCR signaling, affecting cell proliferation, transcriptional activation, and cytokine production. Therapeutic antibodies and Fc fusion proteins blocking this interaction have shown promise in cancer clinical trials. The aAPC(OKT3) PDL1 CHO-K1 Cell Line is a clonal stable CHO-K1 cell line constructed using lentiviral technology, constitutive expression of the OKT3 and human PD-L1 gene. H_PD-1 Reporter Jurkat Cell Line (Cat. GM-C07928) is another stable clonal cell line that expresses the human PD-1 gene, along with signal-dependent expression of a luciferase reporter gene. Co-culturing these cells inhibits TCR signaling and luciferase expression due to the PD-1/PD-L1 interaction. Adding antibodies that block this interaction relieves the inhibition, allowing TCR signaling and luciferase expression to resume. This setup can assess the efficacy and stability of antibodies and biologics that block the PD-1/PD-L1 interaction. |
 |
| PD-1 is an immunosuppressive receptor on activated T and B cells, essential for regulating immune responses to tumor antibodies and self-antigens. Its interaction with ligands PD-L1 or PD-L2 inhibits TCR signaling, affecting cell proliferation, transcriptional activation, and cytokine production. Therapeutic antibodies and Fc fusion proteins blocking this interaction have shown promise in cancer clinical trials. The aAPC(OKT3) PDL1 CHO-K1 Cell Line is a clonal stable CHO-K1 cell line constructed using lentiviral technology, constitutive expression of the OKT3 and human PD-L1 gene. H_PD-1 Reporter Jurkat Cell Line (Cat. GM-C07928) is another stable clonal cell line that expresses the human PD-1 gene, along with signal-dependent expression of a luciferase reporter gene. Co-culturing these cells inhibits TCR signaling and luciferase expression due to the PD-1/PD-L1 interaction. Adding antibodies that block this interaction relieves the inhibition, allowing TCR signaling and luciferase expression to resume. This setup can assess the efficacy and stability of antibodies and biologics that block the PD-1/PD-L1 interaction. |
|
